Compare ASTE & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTE | IMTX |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | Germany |
| Employees | 4468 | 407 |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2003 | N/A |
| Metric | ASTE | IMTX |
|---|---|---|
| Price | $48.69 | $11.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $66.00 | $19.00 |
| AVG Volume (30 Days) | 217.2K | ★ 454.9K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | ★ 784.21 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.72 | N/A |
| Revenue Next Year | $5.44 | $25.91 |
| P/E Ratio | $809.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.83 | $4.93 |
| 52 Week High | $65.69 | $12.41 |
| Indicator | ASTE | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 59.70 |
| Support Level | $47.69 | $9.24 |
| Resistance Level | $49.18 | $12.00 |
| Average True Range (ATR) | 2.31 | 0.61 |
| MACD | -0.63 | -0.01 |
| Stochastic Oscillator | 13.73 | 89.20 |
Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. The company has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.